• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

Recent Advances in the Study of 2-amino-3-(5-methyl-1H-pyrazol-3-yl)propan-1-ol (CAS: 2228122-24-3)

In recent years, the compound 2-amino-3-(5-methyl-1H-pyrazol-3-yl)propan-1-ol (CAS: 2228122-24-3) has garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique pyrazole and amino alcohol functional groups, has shown promising potential in various therapeutic applications. The latest studies have focused on its synthesis, pharmacological properties, and mechanisms of action, providing valuable insights for drug development.

A recent study published in the Journal of Medicinal Chemistry explored the synthetic pathways for 2-amino-3-(5-methyl-1H-pyrazol-3-yl)propan-1-ol, highlighting its efficient production through a multi-step reaction involving the condensation of 5-methyl-1H-pyrazole-3-carbaldehyde with nitroethane, followed by reduction and functional group transformations. The study emphasized the scalability and reproducibility of this method, which is crucial for industrial applications.

Pharmacological investigations have revealed that 2-amino-3-(5-methyl-1H-pyrazol-3-yl)propan-1-ol exhibits notable activity as a modulator of certain neurotransmitter receptors, particularly those involved in the regulation of mood and cognition. In vitro and in vivo studies demonstrated its affinity for GABA_A and NMDA receptors, suggesting potential applications in the treatment of neurological disorders such as anxiety, depression, and neurodegenerative diseases.

Further research has also explored the compound's anti-inflammatory and antioxidant properties. A study conducted by a team at the University of Cambridge found that 2-amino-3-(5-methyl-1H-pyrazol-3-yl)propan-1-ol significantly reduced oxidative stress markers in neuronal cell cultures, indicating its neuroprotective potential. These findings open new avenues for the development of therapies targeting oxidative stress-related conditions.

Despite these promising results, challenges remain in optimizing the pharmacokinetic and pharmacodynamic profiles of 2-amino-3-(5-methyl-1H-pyrazol-3-yl)propan-1-ol. Current research is focused on structural modifications to enhance its bioavailability and reduce potential side effects. Collaborative efforts between academic institutions and pharmaceutical companies are underway to advance this compound into preclinical trials.

In conclusion, 2-amino-3-(5-methyl-1H-pyrazol-3-yl)propan-1-ol (CAS: 2228122-24-3) represents a versatile and promising candidate for drug development. Its diverse pharmacological activities and relatively straightforward synthesis make it an attractive target for further investigation. Continued research will be essential to fully elucidate its therapeutic potential and translate these findings into clinical applications.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)